Biomet and the Accreditation Commission for Health Care (ACHC) Announce A First In Accreditation

WARSAW, Ind.--(BUSINESS WIRE)--Biomet, Inc. announced today that its EBI subsidiary, d/b/a Biomet Trauma and Biomet Spine received accreditation status for Durable Medical Equipment and Orthotics by the Accreditation Commission for Health Care, Inc. (ACHC). Biomet Trauma and Biomet Spine is also being recognized as the first national company to combine ACHC standards along with quality and business management standards including ISO 13485, the Baldridge National Quality Program, and others to attain optimal operations.

Glen Kashuba, President of Biomet Trauma and Biomet Spine commented, “Integrating these standards provides the best model for managing quality and producing products for treating clinically complex patients in businesses such as ours. These Business Management Process Systems (BMPS) have been incorporated into our noninvasive bone growth stimulation and bracing operations. Our system promotes continuous quality improvement, from the receipt of an order through the completion of treatment by the health care provider.”

About the Accreditation Commission for Health Care, Inc. (ACHC)

ACHC, a private, not-for-profit corporation which is certified to ISO 9001:2000 standards, was developed by home care and community-based providers to help companies improve business operations and quality of patient care. Referring to the value of accreditation, ACHC President Tom Cesar indicated, “The survey process leads an organization to examine its policies and practices continually to clarify its strengths and improve its weaknesses.”

Accreditation is a voluntary activity in which healthcare organizations submit to peer review of their internal policies, processes and patient care delivery against national standards. By attaining accreditation, Biomet has demonstrated its commitment to maintain a higher level of competency and strive for excellence in its products, services and customer satisfaction.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 70 countries.

Forward-Looking Statement

This press release contains certain statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are qualified by the inherent risks and uncertainties surrounding future expectations generally, and also may materially differ from actual future experience involving any one or more of such statements. Such risks and uncertainties include our ability to develop and market new products and technologies in a timely manner, and the risk factors as set forth from time to time in Biomet’s filings with the SEC. The inclusion of a forward-looking statement herein should not be regarded as a representation by Biomet that Biomet’s objectives will be achieved. Biomet undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.